Evidence map›Paper›PMID 37364392›Full record

ArticleSchizophrenia research2023

Congenital blindness does not protect against a schizophrenia-related phenotype in rodents.

Stephanie M Perez, Hannah B Elam, Alexandra M McCoy, Angela M Boley, Nicole E Eassa, Daniel J Lodge

Open access · greenAbstract read
In one paragraph

Article in Schizophrenia research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Stephanie M PerezDepartment of Pharmacology and Center for Biomedical Neuroscience, UT Health San Antonio, San Antonio, TX, USA; South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX, USA. Electronic address: perezsm@uthscsa.edu.
Hannah B ElamDepartment of Pharmacology and Center for Biomedical Neuroscience, UT Health San Antonio, San Antonio, TX, USA; South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX, USA.
Alexandra M McCoyDepartment of Pharmacology and Center for Biomedical Neuroscience, UT Health San Antonio, San Antonio, TX, USA; South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX, USA.
Angela M BoleyDepartment of Pharmacology and Center for Biomedical Neuroscience, UT Health San Antonio, San Antonio, TX, USA; South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX, USA.
Nicole E EassaDepartment of Pharmacology and Center for Biomedical Neuroscience, UT Health San Antonio, San Antonio, TX, USA; South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX, USA.
Daniel J LodgeDepartment of Pharmacology and Center for Biomedical Neuroscience, UT Health San Antonio, San Antonio, TX, USA; South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, TX, USA.
The University of Texas Health Science Center at San Antonio · US

Funding

Regulation of ventral hippocampal system functionR01MH090067 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LODGE, DANIEL · 2010 to 2019
$3.5M
Integrated Graduate Training Program in Neuroscience, UTHSCSAT32NS082145 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI David A Morilak · 2013 to 2026
$1.5M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1M
Examining orexinergic modulation of the paraventricular nucleus of the thalamus as a novel therapeutic for PTSD and comorbid psychosisF31MH127890 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ELAM, HANNAH · 2022 to 2023
$43k
Mechanisms contributing to co-morbid psychosis in Alzheimer's diseaseI01BX004646 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · PI LODGE, DANIEL · 2021 to 2024
–
The Orexin System as a Target for PTSD and Comorbid PsychosisI01BX004693 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · PI Daniel Lodge · 2020 to 2026
–
BLRD VA I01 BX004646BLRD VA I01 BX004693NIGMS NIH HHS T32 GM113896NIMH NIH HHS F31 MH127890NIMH NIH HHS R01 MH090067NINDS NIH HHS T32 NS082145
6 · The paper itself

Abstract

backgroundIn 1950, Drs. Chevigny and Braverman authored a book about people's attitudes and prejudices toward the blind, noting that out of the thousands of schizophrenia patients they and others had treated, not one was blind. This led some to the intriguing hypothesis that congenital blindness may provide protection against schizophrenia. In this study, we directly examined whether congenital blindness protects against a schizophrenia-related phenotype in the methylazoxymethanol acetate (MAM) rodent model.

designEnucleation surgeries were performed on pups of MAM- or saline-treated rats on post-natal day 10. Once pups reached adulthood, male and female rats were evaluated for schizophrenia-like phenotypes using behavioral and electrophysiological measures. Consistent with previous work, MAM-treated rats display elevated dopamine neuron population activity, deficits in pre-pulse inhibition of startle, and hypersensitivity to psychomotor stimulants.

resultsBlindness did not protect against any of the MAM-induced phenotypes. Surprisingly, blindness in saline-treated rats caused changes in behavior and dopamine neuron activity. To examine the circadian rhythms of enucleated rats, we performed non-invasive measurements of corticosterone, a steroid hormone known to vary across the light/dark period, revealing blind rats display aberrant (non-cycling) corticosterone levels.

conclusionsAlterations in dopamine neuron activity and associated behaviors observed in blind rats are likely secondary to aberrant circadian regulation. This is the first preclinical study examining whether congenital blindness protects against a schizophrenia-like phenotype. While support of this hypothesis would have led to novel avenues of research and potential novel therapies, the results of current study suggest that blindness does not protect against schizophrenia.

Indexed as

RodentiaSchizophreniaAnimalsBlindnessCorticosteroneDisease Models, AnimalFemaleMaleMethylazoxymethanol AcetatePhenotypeRatsRats, Sprague-DawleyCorticosteroneMethylazoxymethanol AcetateBlindnessDopamineElectrophysiologyEnucleationMAMSchizophrenia

Identifiers

PMID37364392
PMCPMC10529675
OpenAlexW4381995675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.